PEPTIDE PURGATORY: The GLP-1 DIETARY REVOLUTION!

Greetings and welcome to another gut-busting issue of Peptide Purgatory, where we examine the ins and outs of the GLP-1 craze while tracking the aging author’s personal health travails. Friends, this column has become an evolving adventure in interpretation of current medical news with a cynical bent, especially as it is connected to the profit motive. Despite paying dearly for these miracle drugs, we find we are buying into a system designed to extract even more cash from wallets that are deflating as rapidly as our waistlines.

Our lead story is just the latest example of “GLP-1sploitation”, which seems to be following Pat Buchanan’s famous progression: from an idea… to a cause… to a movement… to a racket. Big Pharma generated the idea, its marketing arm amplified the cause to a movement, and now the GLP-1 ancillary market has become a racket. This week: Big Fooda Goes All-Ahead Flank!

GLP-1 Friendly™ PART ONE: Now With More Marketing Than Meaning

It was inevitable.

Once GLP-1 RA drugs such as Mounjaro, Ozempic, Wegovy, and Zepbound escaped the clinic and entered the cultural bloodstream, the food industry was never going to sit this one out. When tens of millions of Americans are injecting a medication that suppresses appetite, slows gastric emptying, and rewires satiety signals, there is only one rational response from Big Fooda: slap a reassuring label on a box and hope nobody asks too many questions.

Thus we arrive at the era of “GLP-1 Friendly” foods.

This phrase sounds medical. It feels clinical. It whispers, don’t worry, this product understands you now. Unfortunately, it means approximately nothing.

Invented Terminology

There is no FDA definition of “GLP-1 friendly” and no defined clinical standard. There is not even a loose consensus. The term exists in the same regulatory limbo as “keto friendly”, “heart healthy,” “clean,” and “artisan,” all of which have been abused so thoroughly that they now function primarily as red flags.

And yet here they are, stacked neatly in grocery freezers and smoothie shops, smiling benignly at people who are already navigating a complex pharmacologic reality.

Let’s get something out of the way early: people using GLP-1 receptor agonists do not have special nutritional requirements. They are not members of a new dietary religion. They do not require blessed foods prepared by certified GLP-1 monks.

What is different is volume. Appetite suppression means fewer calories. Fewer calories mean each bite matters more. That’s it. That’s the whole secret. Protein and fiber matter more because math matters more.

Nothing Novel Here

Protein did not become important when semaglutide hit the market. Fiber was not discovered by Novo Nordisk. Hydration did not suddenly emerge as a concept because someone injected tirzepatide. These are baseline human requirements that have been quietly ignored for decades, now being reintroduced with a trademark symbol.

And this, my friends, is how we end up with absurdities like “GLP-1 friendly” frozen pizzas that manage to deliver heroic amounts of sodium and saturated fat while waving a protein banner like the gigantic American flag at the Super Bowl. Apparently, nausea, indigestion, and acid reflux are “friendly” now. Who knew? Oy, vey, already!

Or how about smoothies proudly branded for GLP-1 users that contain more calories, sugar, and cholesterol than a Krispy Kreme donut? Somewhere, a continuous glucose monitor just emitted a terminal beep as it melted down into a searing blob of steaming electronic waste.

GLP-1sploitation?

This is not nutrition. It is profit-driven opportunism, banking on the vulnerability and gullibility of the GLP-1 patient population.

GLP-1 drugs are neither food preferences nor intolerances nor macros. They are medications that alter neurohormonal signaling and gastrointestinal physiology. You cannot make a food “compatible” with that any more than you can sell “beta-blocker friendly” espresso or “statin approved” cheesesteaks.

But nuance is not the point. Normalization is.

Phase Two Entropy

We are now in phase two of the GLP-1 aftermarket. Phase one was the Wild West: influencers, compounding pharmacies, shortage hysteria, and people injecting mystery peptides sourced from the metabolic equivalent of a vape shop. Phase two is corporate calm. Clean packaging. Official-looking labels. Just enough dietitian quotes to keep the lawyers comfortable.

Phase three, if history is any guide, will be quiet retreat and rebranding once consumers realize the label does not, in fact, protect them from bad food choices.

There is also a more insidious problem lurking here: the resurrection of diet culture, freshly embalmed.

GLP-1 drugs threatened to end the morality play around eating. Appetite regulation without shame was the whole point. But the moment food companies start whispering you still need the right foods to succeed, the old guilt engine sputters back to life. Same script, new fonts.

Only the Beginning…

And mark my words, Turkey readers: we are only at the beginning. Today it’s frozen meals and smoothies. Tomorrow it will be gluten-free, non-fat, GLP-1 friendly popsicles with only 20 grams of added sugar and 5 grams of fiber—available, of course, only if you eat the stick. Serving size: one-third of a popsicle, because personal responsibility builds character.

The truly ironic part? If food companies dropped the drug references entirely and simply said what they mean—higher protein, decent fiber, smaller portions, tolerable fat content—they would be doing something genuinely useful. But “nutrient dense and modestly portioned” doesn’t move units like a vogue pharmaceutical costume party.

So here is the rule of thumb, free of charge: if a food product needs to name-drop your prescription medication to justify itself, it is already losing the argument.

The drug works because it changes physiology. The label works because it changes perception. Confusing the two is not just marketing bullshit—it’s how we end up right back where we started, only with better packaging and worse honesty.

And yes, the popsicles are coming.

---

Part Two: A Case Study in GLP-1sploitation — Replenza

Every trend eventually produces its flagship nonsense. In the GLP-1 economy, that flagship appears to be Replenza.

Several months ago upon seeing a prominent, splashy display, I purchased a jar of the magical elixir from my neighborhood Publix supermarket, thus feeding the Replenza Labs’ bottom line, no doubt benefitting the Wayne, NJ economy.

Replenza bills itself as “physician-formulated GLP-1 support,” a phrase carefully concocted to sound medical while remaining almost aggressively nonspecific. Support how? What? Who? The website never quite says—because saying would require mechanisms, evidence, or at least a testable hypothesis.

Instead, we are offered bullshit.

Special Nutritional Needs

According to Replenza’s marketing, people on GLP-1 medications have special nutritional needs that conveniently align with a proprietary two-product “system.” Appetite suppression, we are told, creates gaps that only Replenza can fill—through a curated blend of protein-adjacent compounds, fiber dustings, electrolytes, adaptogens, enzymes, probiotics, collagen, and an assortment of vitamins that have never met a calorie deficit they couldn’t theoretically help. And what in the bloody hell are adaptogens?

Medical science? Nein, nein — this is nutritional astrology.

Let’s be clear: people eating fewer calories may indeed benefit from adequate protein, fiber, and micronutrients. That is neither controversial nor novel. But it is also not unique to GLP-1 users. Anyone dieting, fasting, ill, stressed, or simply disorganized with food intake falls into the same category. None of this requires a drug-branded supplement ecosystem.

But Replenza does not sell adequacy. It sells relevance.

Science-Backed!

The website leans heavily on authority signaling: “physician-formulated,” “science-backed,” “expert-designed.” There is a board, advisors, and testimonials. What there is not, anywhere, is evidence that this product interacts meaningfully with GLP-1 pharmacology, alters outcomes, preserves lean mass, improves tolerability, or does anything beyond what a competent diet and a basic multivitamin might already accomplish.

What is present is a masterclass in additive buzzword stacking. If you can’t dazzle them with your brilliance, baffle them with your bullshit!

Muscle recovery is promised via BCAAs (branched chain amino acids)—without sufficient total protein to make them useful. Collagen is invoked for skin elasticity, despite being nutritionally incomplete and largely irrelevant to muscle preservation. Digestive health is waved at using two grams of prebiotic fiber, which is less “support” and more “token fiber.” Electrolytes appear largely for aesthetic purposes. Green tea extract—standardized to caffeine—sneaks in for “energy,” because nothing says GLP-1 tolerance like adding stimulants to an already nausea-prone population.

And then there is the formulation itself.

It Floats!

My observation: despite vigorous stirring, shaking, swirling, and genuine effort, the powder does not dissolve. It floats. I can stir it or shake it vigorously, but it still floats. It sits smugly on the surface of the water, unmixed, unbothered, and curiously on-brand. Reminds me of barium sulfate, except barium sulfate has the decency to be honest about wearing the crown of insolubility.

This is not a trivial observation. GLP-1 users already contend with delayed gastric emptying. A product that resists dispersion before ingestion is almost satirical. It is as though the supplement itself is refusing to engage—mirroring its relationship to the drug it claims to support.

The symbolism is exquisite.

A supplement that borrows the legitimacy of a prescription therapy while remaining nutritionally generic, mechanistically detached, and physically insoluble is not malfunctioning. It is expressing its truth. It floats above the liquid the same way its claims float above physiology.

No Harm Done, Other than the Wallet

Replenza does not harm GLP-1 users. That would require meaningful interaction. What it does instead is monetize proximity—standing close enough to a real therapy that consumers may assume relevance where none has been demonstrated.

This is GLP-1sploitation at its most refined.

No outrageous claims.
No explicit lies.
Just careful implication, authoritative tone, and a supplement formula that would look perfectly at home in any wellness aisle if you scraped the acronym off the label.

If Part One of this article examined how food companies learned to whisper “GLP-1” without saying anything, Part Two shows how the supplement industry learned to shout it—while still meaning nothing.

And yes, the popsicles are still coming.

---

Peptide Purgatory, published more or less weekly, mixes one old fart’s ongoing experiment with GLP-1s, metabolism, and medical modernity with a veritable plethora of opinions on the subject. Side effects may include sarcasm, elevated skepticism, and mild tachycardia. Ask your doctor whether Peptide Purgatory is right for you!

For an annotated catalog of all my Peptide Purgatory and Mounjaro updates, visit my Mounjaro Update Catalog page.